NCT01794039View on ClinicalTrials.gov

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Dexamethasone

Given PO

DRUG

Lenalidomide

Given PO

DRUG

Pomalidomide

Given PO

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER